137 related articles for article (PubMed ID: 27313866)
1. Cationic Thiolated Poly(aspartamide) Polymer as a Potential Excipient for Artificial Tear Formulations.
Budai-Szűcs M; Horvát G; Szilágyi BÁ; Gyarmati B; Szilágyi A; Berkó S; Szabó-Révész P; Sandri G; Bonferoni MC; Caramella C; Soós J; Facskó A; Csányi E
J Ophthalmol; 2016; 2016():2647264. PubMed ID: 27313866
[TBL] [Abstract][Full Text] [Related]
2. Thiolated poly(aspartic acid) as potential in situ gelling, ocular mucoadhesive drug delivery system.
Horvát G; Gyarmati B; Berkó S; Szabó-Révész P; Szilágyi BÁ; Szilágyi A; Soós J; Sandri G; Bonferoni MC; Rossi S; Ferrari F; Caramella C; Csányi E; Budai-Szűcs M
Eur J Pharm Sci; 2015 Jan; 67():1-11. PubMed ID: 25445832
[TBL] [Abstract][Full Text] [Related]
3. Impact of Nanostructured Lipid Carriers as an Artificial Tear Film in a Rabbit Evaporative Dry Eye Model.
Niamprem P; Teapavarapruk P; Srinivas SP; Tiyaboonchai W
Cornea; 2019 Apr; 38(4):485-491. PubMed ID: 30681516
[TBL] [Abstract][Full Text] [Related]
4. [Use of a novel polymer, the in-situ gelling mucoadhesive thiolated poly(aspartic acid) in ophthalmic drug delivery].
Horvát G; Budai-Szűcs M; Berkó S; Szabóné-Révész P; Gyarmati B; Szilágyi BÁ; Szilágyi A; Csányi Erzsébet
Acta Pharm Hung; 2015; 85(4):115-21. PubMed ID: 26964399
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of hyaluronic acid to the ocular surface by a polymer-peptide conjugate system for dry eye disease.
Lee D; Lu Q; Sommerfeld SD; Chan A; Menon NG; Schmidt TA; Elisseeff JH; Singh A
Acta Biomater; 2017 Jun; 55():163-171. PubMed ID: 28363785
[TBL] [Abstract][Full Text] [Related]
6. The effect of the antioxidant on the properties of thiolated poly(aspartic acid) polymers in aqueous ocular formulations.
Budai-Szűcs M; Horvát G; Gyarmati B; Szilágyi BÁ; Szilágyi A; Berkó S; Ambrus R; Szabó-Révész P; Sandri G; Bonferoni MC; Caramella C; Csányi E
Eur J Pharm Biopharm; 2017 Apr; 113():178-187. PubMed ID: 28088003
[TBL] [Abstract][Full Text] [Related]
7. [A new approach for better comprehension of diseases of the ocular surface].
Baudouin C
J Fr Ophtalmol; 2007 Mar; 30(3):239-46. PubMed ID: 17417148
[TBL] [Abstract][Full Text] [Related]
8. [Research and development for treating devastating corneal diseases].
Kinoshita S
Nippon Ganka Gakkai Zasshi; 2010 Mar; 114(3):161-99; discussion 200-1. PubMed ID: 20387535
[TBL] [Abstract][Full Text] [Related]
9. Preactivated thiolated pullulan as a versatile excipient for mucosal drug targeting.
Leonaviciute G; Suchaoin W; Matuszczak B; Lam HT; Mahmood A; Bernkop-Schnürch A
Carbohydr Polym; 2016 Oct; 151():743-751. PubMed ID: 27474621
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial.
Simmons PA; Carlisle-Wilcox C; Chen R; Liu H; Vehige JG
Clin Ther; 2015 Apr; 37(4):858-68. PubMed ID: 25659956
[TBL] [Abstract][Full Text] [Related]
11. The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 (
Yagi-Yaguchi Y; Kojima T; Higa K; Dogru M; Ibrahim OM; Shimizu T; Tsubota K; Shimazaki J
Diagnostics (Basel); 2020 Jan; 10(1):. PubMed ID: 31906291
[TBL] [Abstract][Full Text] [Related]
12. Effect of artificial tears on visual performance in subjects with dry eye.
Ridder WH; Tomlinson A; Paugh J
Optom Vis Sci; 2005 Sep; 82(9):835-42. PubMed ID: 16189494
[TBL] [Abstract][Full Text] [Related]
13. [Assessment of Langerhans Cells in the Central Cornea as Tool for Monitoring Inflammatory Changes in Patients with Keratoconjunctivitis sicca under Topical Therapy with Cyclosporine A 0.05% Eye Drops].
Schneider E; Paulsen F; Jacobi C
Klin Monbl Augenheilkd; 2020 May; 237(5):669-674. PubMed ID: 32434251
[TBL] [Abstract][Full Text] [Related]
14. Mucoadhesive Cyclodextrin-Modified Thiolated Poly(aspartic acid) as a Potential Ophthalmic Drug Delivery System.
Budai-Szűcs M; Kiss EL; Szilágyi BÁ; Szilágyi A; Gyarmati B; Berkó S; Kovács A; Horvát G; Aigner Z; Soós J; Csányi E
Polymers (Basel); 2018 Feb; 10(2):. PubMed ID: 30966235
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Tear Supplementation on Ocular Surface Sensations during the Interblink Interval in Patients with Dry Eye.
Dienes L; Kiss HJ; Perényi K; Szepessy Z; Nagy ZZ; Barsi Á; Acosta MC; Gallar J; Kovács I
PLoS One; 2015; 10(8):e0135629. PubMed ID: 26302222
[TBL] [Abstract][Full Text] [Related]
16. Mucins in contact lens wear and dry eye conditions.
Ramamoorthy P; Nichols JJ
Optom Vis Sci; 2008 Aug; 85(8):631-42. PubMed ID: 18677222
[TBL] [Abstract][Full Text] [Related]
17. Graft Versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue.
Shamloo K; Barbarino A; Alfuraih S; Sharma A
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4511-4519. PubMed ID: 31675422
[TBL] [Abstract][Full Text] [Related]
18. Thiomers--from bench to market.
Bonengel S; Bernkop-Schnürch A
J Control Release; 2014 Dec; 195():120-9. PubMed ID: 24993428
[TBL] [Abstract][Full Text] [Related]
19. Novel formulation of glycerin 1% artificial tears extends tear film break-up time compared with Systane lubricant eye drops.
Gensheimer WG; Kleinman DM; Gonzalez MO; Sobti D; Cooper ER; Smits G; Loxley A; Mitchnick M; Aquavella JV
J Ocul Pharmacol Ther; 2012 Oct; 28(5):473-8. PubMed ID: 22554205
[TBL] [Abstract][Full Text] [Related]
20. Is the main lacrimal gland indispensable? Contributions of the corneal and conjunctival epithelia.
Stevenson W; Pugazhendhi S; Wang M
Surv Ophthalmol; 2016; 61(5):616-27. PubMed ID: 26968256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
